The Argentus Capital Management LLC Boosts Position in Teva Pharm Adr (TEVA)

The Argentus Capital Management LLC Boosts Position in Teva Pharm Adr (TEVA)

Argentus Capital Management LLC raised its position in shares of Teva Pharm Adr (NYSE:TEVA) by 88.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,537 shares of the company’s stock after buying an additional 5,427 shares during the period. Argentus Capital Management LLC’s holdings in Teva Pharm Adr were worth $531,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Krilogy Financial LLC increased its position in shares of Teva Pharm Adr by 1.0% in the second quarter. Krilogy Financial LLC now owns 2,635 shares of the company’s stock worth $132,000 after buying an additional 25 shares during the last quarter. Veritable L.P. increased its position in shares of Teva Pharm Adr by 0.5% in the second quarter. Veritable L.P. now owns 5,216 shares of the company’s stock worth $262,000 after buying an additional 26 shares during the last quarter. Toronto Dominion Bank increased its position in shares of Teva Pharm Adr by 0.6% in the second quarter. Toronto Dominion Bank now owns 6,025 shares of the company’s stock worth $304,000 after buying an additional 35 shares during the last quarter. Cribstone Capital Management LLC increased its position in shares of Teva Pharm Adr by 1.3% in the third quarter. Cribstone Capital Management LLC now owns 3,241 shares of the company’s stock worth $144,000 after buying an additional 41 shares during the last quarter. Finally, WESPAC Advisors SoCal LLC increased its position in shares of Teva Pharm Adr by 1.4% in the second quarter. WESPAC Advisors SoCal LLC now owns 3,550 shares of the company’s stock worth $178,000 after buying an additional 50 shares during the last quarter. 54.53% of the stock is currently owned by institutional investors and hedge funds.

Shares of Teva Pharm Adr (NYSE:TEVA) traded down 1.85% during mid-day trading on Thursday, hitting $33.47. 7,498,760 shares of the stock traded hands. Teva Pharm Adr has a one year low of $33.46 and a one year high of $64.31. The stock has a 50 day moving average price of $36.11 and a 200-day moving average price of $45.20. The company has a market cap of $33.97 billion, a P/E ratio of 19.47 and a beta of 0.65.

Teva Pharm Adr (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.02. Teva Pharm Adr had a return on equity of 16.75% and a net margin of 8.81%. The business earned $5.56 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the previous year, the firm earned $1.35 earnings per share. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. On average, analysts forecast that Teva Pharm Adr will post $5.12 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 20th. Investors of record on Monday, December 5th were paid a dividend of $0.34 per share. The ex-dividend date was Thursday, December 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 4.06%. Teva Pharm Adr’s dividend payout ratio (DPR) is presently 67.44%.

TEVA has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Teva Pharm Adr from a “hold” rating to a “sell” rating in a research report on Wednesday, October 12th. Maxim Group downgraded shares of Teva Pharm Adr from a “buy” rating to a “hold” rating and dropped their target price for the stock from $49.00 to $41.00 in a research report on Friday, January 6th. Wells Fargo & Co. reissued a “buy” rating on shares of Teva Pharm Adr in a research report on Monday, October 3rd. Oppenheimer Holdings Inc. reissued an “outperform” rating on shares of Teva Pharm Adr in a research report on Wednesday, December 7th. Finally, Leerink Swann set a $57.00 target price on shares of Teva Pharm Adr and gave the stock a “buy” rating in a research report on Friday, October 7th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Teva Pharm Adr currently has an average rating of “Buy” and an average target price of $56.38.

About Teva Pharm Adr

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharm Adr (NYSE:TEVA).

Related posts

Leave a Comment